SNAP23 Human Pre-designed siRNA Set A

Cat. No.: S1479928

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Descripción general

SNAP23 Human Pre-designed siRNA Set A contains three designed siRNAs for SNAP23 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components SNAP23 siRNA-1: 5 nmol (HPLC) SNAP23 siRNA-2: 5 nmol (HPLC) SNAP23 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condiciones de almacenamiento de almacenamiento

Store at -20°C

Enviado en

Ice chest + Ice pads

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Product Line

Productos biológicos

Application Protocols

Tested/validated applications, recommended dilutions, and protocol specifics are Not specified for this item; refer to CoA/Spec Sheet.

General note: For siRNA transfection into mammalian cells, follow the transfection reagent manufacturer’s protocol and optimize siRNA dose, complexation time, and cell density for your system. Include appropriate negative and positive control siRNAs to interpret knockdown outcomes. Because protocol parameters are reagent‑ and cell line–dependent, authoritative instructions should be taken from the CoA/Spec Sheet and SDS accompanying this SKU.

Biological Roles

Target context (literature/general; not item‑specific claims):

• SNAP23 (synaptosomal‐associated protein 23) is a ubiquitously expressed t‑SNARE protein implicated in vesicle docking and membrane fusion events in non‑neuronal cells. It forms SNARE complexes with syntaxins and VAMPs to mediate exocytosis and trafficking.
• Functional processes include regulated secretion (e.g., insulin granules in beta cells, immune cell degranulation), plasma membrane repair, and receptor trafficking. Post‑translational modifications (e.g., phosphorylation, palmitoylation) modulate SNAP23 localization and activity.
• Cellular localization: Predominantly plasma membrane/cytosolic face; can also localize to endosomal or Golgi membranes depending on cell type (literature).
• Genetic perturbation (RNAi/CRISPR) is frequently used to dissect SNARE complex assembly, cargo release, and signaling crosstalk.

Research utility of siRNA targeting SNAP23 (general guidance):

• Enables temporal, reversible loss‑of‑function without genomic alteration—useful where permanent knockout is lethal or adaptive.
• Facilitates pathway mapping via combined knockdown of SNAP23 with other SNAREs or regulatory kinases to assess epistatic relationships.

Important notes:

• Off‑target effects and innate immune activation can confound interpretation; use multiple independent siRNAs, low doses, and appropriate non‑targeting controls to confirm specificity.
• Downstream phenotype timing should consider SNAP23 protein half‑life and pathway kinetics; corroborate mRNA suppression (qPCR) and protein reduction (immunoblot) for robust conclusions.

No medical or clinical claims are made; this product is for research use only.

Buffer Applications

Item-specific buffer formulations and recommended reconstitution buffers are not provided. Refer to the CoA/Spec Sheet for definitive instructions.

General/literature guidance for siRNA handling (not item‑specific):

• Reconstitution: RNase‑free water or 1× TE buffer (10 mM Tris–HCl, 1 mM EDTA, pH 7.5–8.0). Prepare concentrated stocks (e.g., 20–100 µM) and aliquot to avoid freeze–thaw.
• Working solutions: Dilute in serum‑free medium for complexation with transfection reagents, then add to complete medium after complex formation per reagent manufacturer instructions.
• Stability considerations: Avoid divalent cation–rich buffers during storage unless chelated (TE). Maintain neutral pH to limit backbone cleavage; avoid repeated warming above room temperature.
• RNase control: Use certified RNase‑free plasticware and filter tips. Clean benches with RNase decontamination solution.

These are general best practices; adapt to your transfection reagent and cell model.

Green Alternatives

While siRNA reagents themselves pose minimal environmental hazards compared with many small‑molecule solvents, the associated workflows can be optimized for greener laboratory practice.

Item-specific environmental attributes: Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance (not item‑specific):

• Transfection reagents: Prefer biodegradable, serum‑compatible lipids/polymers that permit lower doses and reduced cytotoxicity, thereby decreasing repeat experiments and waste.
• Buffers and disposables: Use concentrated buffer stocks to minimize packaging; choose certified RNase‑free, recyclable plastics where feasible.
• Cold chain: Consolidate shipments and coordinate deliveries to minimize dry ice/ice pack usage. Store as recommended to prevent spoilage and re‑orders.
• Decontamination: Replace harsh RNase inhibitors containing volatile organics with aqueous, non‑volatile RNase decontamination solutions when validated.

Comparison (general):

• Traditional cationic lipids vs. next‑gen lipid nanoparticles (LNPs): LNPs can improve delivery efficiency at lower siRNA loads, reducing reagent consumption; however, they may require specialized preparation and have their own environmental footprint.
• Ethanol‑based precipitation vs. column clean‑ups: Columns can reduce organic solvent use but add plastic waste; evaluate life‑cycle impacts based on experiment scale.

Trade‑offs should be evaluated using local waste streams, recycling programs, and institutional sustainability policies.

Pharmaceutical Uses

This product is supplied strictly for research use only.

• Regulatory/compendial status: Not specified for this item; refer to CoA/Spec Sheet.
• Excipient/formulation roles: Not applicable—this SKU is a research‑grade gene silencing reagent, not intended for human or veterinary administration.
• Manufacturing/CMC context (general note): Sequence‑defined oligonucleotides used for therapeutic development require GMP manufacturing, comprehensive impurity profiling, and regulatory documentation. This research product is not qualified for such use.

No therapeutic, diagnostic, or clinical claims are made.

Physical Properties

Item-specific physicochemical specifications have not been provided for this siRNA product. Where applicable, consult the CoA/Spec Sheet for exact values.

Item-specific (from Product Data):

• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General/literature properties for siRNA (for planning only; not item-specific specs):

• Typical length: 19–27 base pairs with 2‑nt 3′ overhangs.
• Approximate molecular mass: ~13–17 kDa for 21‑mer duplex without modifications; increases with length/modifications (literature).
• Solubility: Highly water-soluble in RNase‑free water or low‑ionic strength buffers (e.g., 10 mM Tris, pH 7.5–8.0) (literature).
• Charge: Polyanionic due to phosphate backbone; does not partition into nonpolar solvents.
• UV absorbance: Strong at 260 nm; A260 of 1.0 corresponds to ~40 µg/mL for single‑stranded RNA (literature). Duplex extinction coefficients depend on sequence; item-specific ε260: Not specified for this item; refer to CoA/Spec Sheet.
• pH stability (literature): Most stable near neutral pH; depurination/transesterification accelerated under strong acid/base. Avoid prolonged >65 °C heating in aqueous buffers.

Refractive index, density, mp/bp, logP, pKa: Not applicable or not meaningful for large polyanionic oligonucleotide duplexes; not specified for this item.

Quality and Grades

Item-specific grade/purity details are not provided in the Product Data. Please refer to the CoA/Spec Sheet for exact specifications (e.g., purity method, residual solvents/salts, endotoxin limits, and QC assays).

General considerations for siRNA quality (literature/industry practice; not item‑specific):

• Purity level: siRNA duplexes are commonly supplied desalinated, HPLC‑purified, or PAGE‑purified. Higher purity reduces truncated species and improves potency/reproducibility.
• Identity & composition: Verified by mass spectrometry (e.g., MALDI‑TOF/ESI), UV A260 quantification, and strand stoichiometry confirmation. Duplex annealing and correct strand ratios are critical for activity.
• Residuals & contaminants: Salts/buffers from synthesis (e.g., TEA, acetonitrile traces), and pyrogen/endotoxin for cell‑based use. For sensitive mammalian cell work, low endotoxin and bioburden controls are recommended.
• Functional QC: Knockdown verification in a reporter or endogenous target assay is often used for design validation by vendors; item‑specific validation status for this set is Not specified for this item; refer to CoA/Spec Sheet.
• Stabilizers/modifications: Chemical modifications (e.g., 2′‑O‑Me/2′‑F, PS) can elevate nuclease resistance and reduce off‑target effects. Presence/extent for this item: Not specified for this item; refer to CoA/Spec Sheet.

What “Pre‑designed siRNA Set A” typically implies (literature): a panel of multiple, non‑overlapping siRNA duplexes against the same gene to enable screening and pooled/consensus knockdown. Exact count/sequences for this SKU: Not specified for this item; refer to CoA/Spec Sheet.

Reaction and Applications

This product is designed for RNA interference (RNAi) applications to silence human SNAP23 expression in research settings.

Item-specific tested applications: Not specified for this item; refer to CoA/Spec Sheet.

General/literature applications (not item‑specific):

• Transient knockdown in mammalian cells to study SNAP23 function in vesicle docking/fusion pathways and SNARE complex biology.
• Co‑transfection with reporter constructs for pathway dissection, epistasis analyses, and rescue experiments using siRNA‑resistant SNAP23 cDNA.
• Phenotypic screening: Using a set of multiple siRNAs to confirm on‑target effects via concordant phenotypes and to mitigate off‑target bias.
• Proteomics/transcriptomics: Quantify downstream changes by Western blot, qPCR, or RNA‑seq following knockdown to map SNAP23‑dependent networks.

Practical tips (literature):

• Use at least two independent siRNA duplexes (or a pool) to validate on‑target effects; include non‑targeting and positive control siRNAs.
• Optimize transfection reagent, cell density, and dose (e.g., 5–50 nM final siRNA) to balance potency and viability.
• Assess knockdown kinetics: mRNA suppression is often detectable by 24 h, protein reduction maximal by 48–96 h depending on protein half‑life.
• Reduce off‑targets: Use the minimal effective dose, chemical stabilization patterns that reduce innate immune sensing, and rigorous controls.

All application details above are general best practices and should be adapted to your cell system and delivery method.

Reaction Conditions

For siRNA, “reaction conditions” translate to delivery and knockdown conditions in cells. No item-specific conditions are provided; consult the CoA/Spec Sheet and your transfection reagent manual.

General/literature guidance (not item‑specific):

• Cell density: 40–70% confluence at transfection often balances viability and uptake.
• Dose range: 5–50 nM final siRNA is a common starting window; titrate to the minimal effective dose to reduce off‑targets.
• Complexation: Follow transfection reagent vendor ratios (e.g., lipid:siRNA). Incubate complexes in serum‑free medium 10–20 min before addition to cells.
• Medium: Replace with complete medium after 4–24 h exposure depending on reagent tolerance; some protocols allow direct addition in complete medium.
• Timing: Assess mRNA levels at 24–48 h; protein levels at 48–96 h, depending on protein half‑life.
• Controls: Include non‑targeting siRNA, a positive control siRNA (known knockdown), and a mock transfection. Where possible, perform rescue with siRNA‑resistant SNAP23 cDNA.
• Readouts: qPCR for SNAP23 mRNA, Western blot/ELISA for protein, and functional assays of vesicle fusion/trafficking as relevant.

These parameters are general best practices and should be empirically optimized for each cell line and delivery method.

Safety and Handling

Always handle oligonucleotides using good laboratory practices and consult the product SDS for authoritative, item‑specific safety information.

Item-specific hazard info from Product Data:

• Signal Word: Not specified for this item; refer to SDS.
• H‑Statements: Not specified for this item; refer to SDS.
• GHS Classification/Pictograms: Not specified for this item; refer to SDS.

General safety guidance (literature/best practice):

• Expected hazards: Synthetic siRNAs are generally considered of low acute toxicity; however, dust/aerosol may cause mechanical irritation. Avoid inhalation, ingestion, and contact with eyes/skin.
• PPE: Lab coat, gloves (nitrile), safety glasses. Change gloves frequently to mitigate RNase contamination when preparing solutions.
• Engineering controls: Work in a clean area; for lyophilized powders, minimize dust formation. Use RNase‑free tools and consumables.
• Incompatibilities: RNA is degraded by RNases present on skin/surfaces and in environmental contamination. Decontaminate benches/equipment with RNase decontamination solutions and use sterile, nuclease‑free water/buffers.
• First aid (general): If inhaled—move to fresh air. Skin/eye contact—rinse with water for several minutes; remove contaminated clothing. If ingested—rinse mouth. Seek medical attention as needed. Provide SDS to healthcare providers.
• Spill & disposal: Avoid creating aerosols. Wipe with RNase‑decontamination solution or 10% bleach followed by water. Dispose in accordance with institutional and local regulations.
• Transport/storage risks: Avoid repeated freeze–thaw. Keep sealed, desiccated, and cold to limit hydrolysis/nuclease degradation.

Defer to the SDS for definitive hazard classification and response measures.

Solvent Selection

As an RNA oligonucleotide, this product is intended for reconstitution in aqueous, nuclease‑free media.

Item-specific guidance: Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance for siRNA (not item‑specific):

• Primary solvents: RNase‑free water, or 1× TE (10 mM Tris–HCl, 1 mM EDTA, pH 7.5–8.0). Many users prefer water for stocks and add buffer upon dilution to working solutions to minimize EDTA interference in divalent cation‑dependent assays.
• Recommended stock concentrations: 10–100 µM are commonly prepared; choose based on transfection protocol and expected working range (literature).
• Avoid: Nonpolar organic solvents (insoluble), strong acid/base (RNA hydrolysis), and unverified lab water (risk of RNase contamination). Ethanol/isopropanol are used for precipitation but not for final storage.
• Compatibility: siRNA is compatible with most mammalian cell culture media after complexation with a transfection reagent. Divalent cations and serum proteins can impact delivery efficiency; consult transfection reagent guidance.

Comparison (general):

• RNase‑free H2O: Maximum flexibility; no chelators; best for short‑term stock storage at −20 °C.
• 1× TE: Improved stability against metal‑catalyzed hydrolysis; EDTA may impact Mg2+‑dependent enzymes.
• PBS: Ionic strength may affect complexation with some lipid reagents; often avoided for initial complex formation.

Storage and Reconstitution

Item-specific storage/shipping (from Product Data):

• Storage Conditions: Store at −20 °C
• Shipped In: Ice chest + Ice pads

Additional item-specific details (e.g., lyophilized vs. solution, stabilizers, recommended diluent, concentration, and aliquoting guidance): Not specified for this item; refer to CoA/Spec Sheet.

General/literature recommendations for siRNA handling (not item‑specific):

• Upon receipt: Allow container to equilibrate to room temperature in a desiccated environment before opening to prevent condensation.
• Reconstitution: Use RNase‑free water or 1× TE (pH 7.5–8.0) to prepare a concentrated stock (e.g., 20–100 µM). Vortex gently and incubate on ice 10–15 min to ensure full dissolution.
• Aliquoting: Dispense into single‑use aliquots to avoid repeated freeze–thaw cycles. Store aliquots at −20 °C (short to mid‑term) or −80 °C (long‑term) in low‑bind, RNase‑free tubes.
• Thawing: Thaw on ice; mix by gentle flicking. Avoid vigorous pipetting/foaming.
• Light and moisture: Protect from moisture; light sensitivity is minimal, but store in opaque containers to protect any dye‑labeled constructs if applicable.

For authoritative, item‑specific instructions, consult the CoA/Spec Sheet that accompanies SKU S1479928.

Structure and Identity

This product is a pre-designed small interfering RNA (siRNA) reagent targeting human SNAP23. As an siRNA set, it comprises double‑stranded RNA oligonucleotides for RNA interference (RNAi)–mediated gene silencing.

• Product type: synthetic siRNA duplexes (research reagent)
• Target gene: SNAP23 (human)
• Synonyms for target (general/literature): synaptosomal-associated protein 23; a t-SNARE involved in membrane fusion (literature)
• Oligonucleotide chemistry: Typically 19–27 bp duplexes with 2‑nt 3′ overhangs (literature, general for siRNA). Item-specific sequence/chemistry: Not specified for this item; refer to CoA/Spec Sheet.
• Chemical identifiers (item-specific):
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • CAS, InChIKey, SMILES, CID: Not applicable/not specified for siRNA reagents; refer to CoA/Spec Sheet if provided.

Structural description (general/literature):

• 2D representation: two antiparallel RNA strands (sense and antisense) with ribose–phosphate backbones and nucleobase pairing (A:U, G:C). Antisense (guide) strand incorporates into RISC to direct target mRNA cleavage/suppression.
• Optional stabilizations (e.g., 2′‑O‑Me, 2′‑F, phosphorothioate) are commonly used to enhance nuclease resistance and reduce immunostimulation (literature). Presence/extent of such modifications for this product: Not specified for this item; refer to CoA/Spec Sheet.

Note: This section distinguishes general features of siRNA architecture from item‑specific identifiers, which are not provided in the current Product Data.

Synthetic Utility

Not typically applicable. This product is a functional biological reagent (siRNA) rather than a small‑molecule building block or catalyst.

General/literature note: Chemical synthesis of siRNA involves solid‑phase phosphoramidite chemistry followed by deprotection, cleavage, desalting, and purification (HPLC/PAGE). Such information is relevant to manufacturing, not to end‑user synthetic transformations. For laboratory users, the primary utility is in gene silencing–based studies rather than chemical synthesis.

Target Specificity

Only item-specific information from the Product Data is provided here.

• Target: SNAP23
• Species reactivity: Human
• Product format/type: Pre‑designed siRNA Set A

Additional details such as duplex count, sequences, modification patterns, and validated off‑target analyses are Not specified for this item; refer to CoA/Spec Sheet.

Preguntas frecuentes

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.